Subject Category: Cancer
Differentiation therapy by retinoic acid (RA) remains an important cancer treatment modality for the management of some types of cancer (e.g., acute promyelocytic leukemia (APL)). RA, the active form of vitamin A, signals through three RA receptors (RARa, -b, and -g) and three retinoid-Xreceptors (RXRa, -b, and -g), which form RXR/RAR heterodimers. These receptors are the in vivo mediators of the RA-induced signaling and control a plethora of gene regulatory programs acting as ligand-dependent transcription factors. 1 RA regulates cell growth, differentiation and death, and thus plays major roles in embryonic development and tissue remodeling. 2 RA has been also shown to inhibit breast cancer cell growth and prevent mammary carcinogenesis in animal models, a process that generally involves the induction of apoptosis and cell-cycle arrest. 3 Despite the remarkable efficacy of all-trans RA in APL, 4 it has shown limited success in clinical trials of breast cancer. 5, 6 Research focused on the actions of the RARs, on the regulation of their expression, and on the identification of their target genes is key to improve RA efficacy and to develop new therapies for cancer disease.
For the past 25 years, a special attention has been given to adjuvants or enhancers of immunity for cancer therapy. The Toll-like receptor (TLR) family recognizes pathogenassociated molecular patterns specific for microbial components. 7, 8 Mainly expressed in innate immune cells, TLRs recognize these motifs and trigger innate immune activation and, subsequently, adaptive immunity. Several TLR agonists are currently being tested as adjuvants for anticancer vaccines and therapies. 9 TLR3 acts as a critical sensor of double-stranded RNA (dsRNA) and has been found in endosomal compartments or at the cell surface of conventional dendritic cells, as well as in a variety of epithelial cells. 8 In a similar way to natural dsRNA from viral origin, the synthetic dsRNA analog polyinosinic-polycytidylic acid (poly(I:C)) binds TLR3 leading to the activation of the transcription factors nuclear factor-kB (NF-kB) and interferon regulatory factor 3 (IRF3), and of kinases such as p38 and c-Jun N-terminal kinase (JNK), promoting the synthesis of proinflamatory cytokines, costimulatory molecules and type I interferons (IFNs). In fact, poly(I:C) was found to be a strong IFN inducer. 10, 11 Additional cytosolic dsRNA receptors-RA-inducible gene-1 (RIG-1) and melanoma differentiationassociated antigen-5 (MDA-5)-have recently been identified. 12 Because poly(I:C) promotes the activation of the innate immunity and thus of long-lasting T cells immunity, 13 it is of great interest as a potential anti-cancer agent. [14] [15] [16] [17] Importantly, it has recently been reported that TLR3 agonists, especially poly(I:C), can directly kill cancer cells through induction of apoptosis.
14 Thus, TLR3 activation may cause tumors to regress by increasing apoptosis of cancer cells in a cell-autonomous manner and by directly or indirectly recruiting leukocytes, resulting in tumor lysis by natural killer and cytotoxic T-cells.
In this study, we report that RA-induced growth inhibition is accompanied by induction of TLR3 gene expression in breast cancer cells. We found that treatment with RA and poly(I:C) synergistically inhibited the growth and induced the apoptosis of breast cancer cells, which is accompanied by the concomitant upregulation of dsRNA receptor expression TLR3, RIG-1, MDA-5 and the dsRNA-activated protein kinase (PKR), and their downstream transcriptional target genes, interleukin-8 (IL-8), chemokine (C-C motif) Ligand 5 (CCL5), C-X-C motif Chemokine 10 (CXCL10) and IFNb. Our results suggest that RA and poly(I:C) co-treatment induces cell death in a TLR3-dependent manner, which involves type I IFN autocrine signaling, caspase-8 and caspase-3 activation as well as the expression and activity of the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
Results
RA and poly(I:C) co-treatment inhibits breast cancer cell growth. Data obtained in our laboratory indicated that 9-cis-retinoic-acid (9cRA) induce the upregulation of TLR3 in SK-BR-3 cells (AMJ-L, unpublished results). In order to corroborate these data and to increase the relevance of the results, we decided to broaden the study and analyzed TLR3 expression in a panel of six human breast cancer cell lines after 9cRA treatment. 9cRA upgregulated TLR3 mRNA expression in all tested cell lines (Figure 1a ). Since it is well recognized that RA and TLR3 agonists, on their own, can exert anti-proliferative effects in certain breast cancer cells, we decided to investigate the effect of a combined treatment of both. For this purpose, we performed dose-response experiments in several breast cancer cell lines treated with 9cRA in the presence or absence of poly(I:C). As expected, treatment of SK-BR-3 cells with 9cRA at the pharmacological concentration of 10 À 6 M displayed a weak growth inhibitory effects at 48 h, whereas no effects on cell proliferation could be seen after addition of poly(I:C) alone at any concentration used. Interestingly, 9cRA and 50 mg/ml poly(I:C) co-treatment exerted profound anti-proliferative effects in these cells (Figure 1b) . At this concentration, 9cRA and poly(I:C) cotreatment inhibited cell growth in a time-dependent manner in SK-BR-3 cells, by about 60% and above 80% at 48 h and 72 h, respectively (Supplementary Figure S1) . Similar results were obtained for H3396, ZR-75-1, and T47D cells. However in these cells, poly(I:C) alone was already able to inhibit growth, while 9cRA increased the sensitivity of the cells to the anti-proliferative action of poly(I:C). Taken together, these results suggest that the two signaling pathways can cooperate in the control of breast cancer cell proliferation.
RA and poly(I:C) co-treatment induces caspasedependent cell death. In order to find out whether cell death contributes to the anti-proliferative effect induced by 9cRA and poly(I:C) co-treatment in SK-BR-3 cells, we analyzed the sub-G1 cell-population as a measure of cell death. As shown in Figure 2a , neither the treatment with 9cRA nor with poly(I:C) alone had any noticeable effect on that has to be degraded in order to allow apoptosis induction. In contrast, no effect of CHX could be detected in the other two cell lines (H3396 and T47D), suggesting that other mechanisms could also account for apoptosis resistance to 9cRA/poly(I:C).
Next, we decided to analyze more thoroughly the apoptotic pathway(s) activated in SK-BR-3 and ZR-75-1 cells consequently to 9cRA/poly(I:C) co-treatment. Our results show that 9cRA cooperates with poly(I:C) to induce apoptosis in a dosedependent manner in SK-BR-3 cells (Figure 2b ). Since 9cRA is a pan-RAR and -RXR agonist, we used specific agonists to test the contribution of each of these receptors to the cell death induction promoted by 9cRA and poly(I:C) co-treatment. As shown in Figure 2c , while TTNPB, an RAR-agonist, clearly cooperates with poly(I:C) to induce the apoptosis of SK-BR-3 cells, the specific RXR-agonist LG-100268 does not affect the viability of these cells, showing that RARs are the receptors involved. Cooperation between 9cRA and poly(I:C) to induce apoptosis seems specific for poly(I:C) since another dsRNA, polyadenylic-polyuridylic acid (poly(A:U)), does not synergize with 9cRA to induce apoptosis in SK-BR-3 cells (Figure 2d ). Moreover, 9cRA and poly(I:C) co-treatment activates caspase-8 and caspase-3 as assessed by western blot in SK-BR-3 cells (Figure 2e ). Taken together, these results suggest that an RAR-mediated caspase-dependent cell death mechanism contributes to the 9cRA/poly(I:C)-driven anti-proliferative effects in breast cancer cells.
RA and poly(I:C) co-treatment enhances the expression and signaling of dsRNA sensors. Since our observations show that TLR3 mRNA is upregulated by 9cRA in breast cancer cell lines, we next sought to investigate whether 9cRA and/or poly(I:C) regulate the expression of other dsRNA sensors in SK-BR-3 and ZR-75-1 cells that could act as potential mediators of 9cRA/poly(I:C)-driven apoptosis. As shown in Figure 3a , TLR3 mRNA was upregulated by 9cRA but not by poly(I:C) in SK-BR-3 cells. Importantly, 9cRA/ poly(I:C) co-treatment synergistically induces the expression of TLR3 (Figure 3a) . Similar results were seen at the protein level (Figure 3c ). RIG-1 mRNA was also strongly upregulated by 9cRA alone, while no significant induction of MDA-5 and PKR expression by 9cRA was seen in SK-BR-3 cells. Note that, on its own, poly(I:C) did not induce the expression of these genes in this cell line. Interestingly, the combination of both 9cRA and poly(I:C) resulted in a synergistic induction of RIG-1, MDA-5 and PKR above the levels seen with either compound alone (Figure 3e) . Similar results were obtained with ZR-75-1 cells albeit induction of these genes by 9cRA was lower than in SK-BR-3 cells, and poly(I:C) alone notably regulated the expression of all these genes. As it was observed for SK-BR-3 cells, 9cRA/poly(I:C) co-treatment synergistically induced the expression of these genes in ZR-75-1 cells (Figure 3b , d, and f). These data suggest that 9cRA and poly(I:C) crosstalk to amplify an innate immune signaling pathway that drives breast cancer cells to apoptosis.
Next, we decided to investigate whether 9cRA and poly(I:C) crosstalk produces an amplification of dsRNA receptor signaling by analyzing the expression of several downstream transcriptional targets in breast cancer cells such as IFNb, and some interleukins and chemokines involved in the activation and chemoattraction of immune cells. As shown in Figure 4 , the expression of IFNb, IL-8, CCL5, and CXCL10 were synergistically induced after 9cRA/poly(I:C) co-treatment, but not with either treatment alone.
Type I IFN signaling is involved in RA/poly(I:C)-induced apoptosis. As IFNb has been described as a potent apoptotic inducer in several cell models, we sought to investigate whether that could be also the case for SK-BR-3 cells. Despite the dramatic induction of IFNb by TRAIL expression is induced by RA/poly(I:C) co-treatment in breast cancer cells. The activation of caspase-8 implies the potential involvement of the apoptotic extrinsic pathway triggered by 9cRA/poly(I:C) co-treatment. TRAIL, an IFN target gene, is a death ligand that triggers cell death via the extrinsic pathway. 18 Since RA induces apoptosis of cancer cells by inducing TRAIL expression 19, 20 and TRAIL is involved in poly(I:C)-driven apoptosis in endothelial cells, 21 we reasoned that TRAIL could be a mediator of 9cRA/poly(I:C) pro-apoptotic signaling in breast cancer cells. As expected, 9cRA induced TRAIL mRNA level (E10-fold) in SK-BR-3 cells, and a similar induction was observed with poly(I:C) alone. Importantly, 9cRA/poly(I:C) co-treatment led to a synergistic upregulation of TRAIL mRNA (41500-fold), as shown in Figure 6a . Protein immunoblotting revealed that synergistic upregulation of TRAIL by 9cRA/poly(I:C) co-treatment occurs in a timedependent manner and correlates with caspase-3 and caspase-8 activation (Figure 6b) . Similar results were obtained in ZR-75-1 cells with the only difference that poly(I:C), on its own, strongly induced both TRAIL mRNA and protein levels in these cells (Figure 6c and d) . Therefore, these results indicate that 9cRA and poly(I:C) signaling can cooperate to synergistically induce TRAIL and its expression correlates with the activation of different apoptotic markers. 
Discussion
In the present study, we provide evidence that RA is able to induce the expression of TLR3, allowing breast cancer cells to sense and respond to the synthetic dsRNA poly(I:C), and driving breast cancer cells to apoptosis. Apoptosis induced by this combination treatment is a caspase-, TLR3-, type I IFN-and TRAIL-signaling-dependent process. Our findings suggest that combined treatments with RA may improve the apoptotic cellular response in those cancer cells insensitive or with low sensitivity to the anti-tumor action of synthetic dsRNA.
The anti-tumor activity of poly(I:C) is well known since decades. Recent data have shown that poly(I:C) binding to TLR3 triggers apoptosis of human cancer cells. 14, 22 In addition, poly(I:C) has indirect anti-tumor activities since it is a potent inducer of type I IFNs, 23 which are known to exert anti-tumor actions on a variety of tumor cells. It has been shown that IFNs have anti-proliferative and proapoptotic effects in an extensive panel of malignant cells. 24 Since the late 1960s, numerous studies have been performed using synthetic dsRNA to inhibit tumors in experimental animal models as well as in clinical trials. The anti-tumor Effects of RA and poly(I:C) on breast cancer cells AR Bernardo et al activity of poly(I:C) is mainly due to its ability to induce IFNs, which either kill directly tumor cells or enhance the host immune response. On the other hand, RA, due to its strong anti-proliferative and differentiative potential, has been widely used in both cancer therapy and cancer prevention. 25 RA derivatives are currently used in the treatment of APL and cutaneous T-cell lymphomas, but they are also effective on B-cell malignancies. 3 In addition to the induction of differentiation, RA is able to initiate several other biological programs that may contribute to its therapeutic potential. Indeed, it has been shown that RA induces apoptosis of APL cells and APL patient blasts through selective paracrine action of TRAIL. 19 In breast cancer cells, previous data have shown that RA inhibits the proliferation of a large number of cell lines and xenograft models by modulating the expression of several genetic programs. In addition to directly target neoplastic cells, accumulated evidence indicate that RA may also exerts immunomodulatory effects. To a certain extent, the efficacy of RA in cancer treatment may reside in its ability to also modulate the function of immune effectors. 26 Our findings show that RA induces TLR3 expression in several breast cancer cell lines, suggesting that TLR3 activation may play an important role in RA action in breast cancer cells. Importantly, RA regulation of TLR3 expression may be indirect or depend on intermediary short-lived protein(s), since incubation with CHX abrogates induction of TLR3 mRNA by RA (data not shown). It has been previously shown that the TLR3 promoter contains an ISRE/IRF-E and a STAT-binding site. 27 These consensus sites might regulate the response of TLR3 to RA since it has been shown that RA can control the expression and activity of transcription factors such as IRF1 and STAT1 in cancer cells. 20, [28] [29] [30] [31] Further studies will be required to know the molecular mechanism underlying the regulation of TRL3 expression by RA. Based on our finding that TLR3 expression is enhanced by RA, we hypothesized that RA could cooperate with TLR3 agonists to enhance their anti-cancer action. In our study, we found that (i) RA is able to sensitize breast cancer cells to the antiproliferative effects of poly(I:C) and (ii) RA does not induce a noticeable cell death in breast cancer cells by itself but it synergizes with poly(I:C) to increase cell death. This synergy is specific for poly(I:C) since another TLR3 ligand such as poly(A:U) failed to cooperate with RA, even at the relative high concentration used in our study. Our results suggest that the increased levels of TLR3 obtained following treatment with RA are sufficient to allow signaling by poly(I:C) but not by poly(A:U). In this regard, previous reports have shown a similar activity for both TLR3 ligands but with a significant lower potency for poly(A:U) compared with poly(I:C). 32, 33 Probably, differences in potency might be proportional to the ability of these ligands to mediate TLR3 multimerization and subsequent signaling. Alternatively, a different affinity of TLR3 for poly(I:C) and poly(A:U) could also account for the differences found between these two TLR3 ligands.
Notably, our results also show that RA and poly(I:C) synergistically induce the expression of TLR3, MDA-5, RIG-1, and PKR, thus amplifying the cellular response to poly(I:C). Increased expression of these dsRNA sensors could enhance the susceptibility of breast cancer cells to poly(I:C)-induced apoptosis as it occurs in other cell systems where ectopic overexpression of TLR3 increases the sensitivity of low TLR3-expressing neuroblastoma cells to poly(I:C). 34 Thus, our results show that RA is able to modulate the expression of key innate immune players allowing breast cancer cells to sense and respond to mimickers of viral dsRNA such as poly(I:C). Given that knockdown of TLR3 completely abolished RA/poly(IC) induced apoptosis in SK-BR-3 cells, it is unlikely that RIG-1 or other dsRNA sensors play an important role in RA/poly(I:C)-induced apoptosis although we cannot discard that these cytoplasmic dsRNA receptors could be involved in other aspects of RA/poly(I:C) crosstalk.
In response to RA/poly(I:C) treatment, SK-BR-3 cells produce high amounts of IFNb and TRAIL as well as the activation of caspase-3 and caspase-8. It has been shown that type I IFNs can directly contribute to tumor cell death in a caspase-dependent manner, 35 or indirectly contribute to the upregulation of cytotoxic molecules such as TRAIL. 36, 37 Molecular events involved in cell death induced by RA/ poly(I:C) co-treatment include type I IFNR signaling that seems to be required but not sufficient for apoptosis, since recombinant IFNb, per se, or in combination with RA does not recapitulate the proapoptogenic activity of RA/poly(I:C) in breast cancer cells. However, recombinant IFNb and poly(I:C) co-treatment is able to induce apoptosis in breast cancer cells as it has been shown for other cell types. Thus, our findings suggest that, besides of type I IFN signaling, additional signals coming from poly(I:C) are required to induce a fully apoptotic program. It is likely that IFNb contributes to TRAIL induction by RA/poly(I:C) in breast cancer cells, as it occurs in other cellular systems but that additional signals, apart from IFNb, are required to sense and transduce TRAIL death signaling. Considering the contribution of type I IFNs in apoptosis induced by RA/poly(I:C), it is tempting to speculate that differences in the ability to produce and/or to respond to type I IFNs consequently to RA/poly(I:C) co-treatment could explain the observed variability in RA/poly(I:C)-induced cell death in different cellular contexts. On the other hand, it has been shown that RA can synergize with IFNs to induce several biological responses. In that sense, RA directly induces the expression of two transcription factors, STAT1 and IRF1, that play central roles in the IFN signal transduction pathways. 20, 28, 29, [38] [39] [40] [41] In addition, it has been proposed that RA may indirectly activate IRF1 expression by a mechanism involving NF-kB. 42 RA also enhances IFNb-induced expression and phosphorylation of STAT1 in human leukemia cells 43 explaining the RA/IFN synergy found in these cells. Therefore, it is possible that RA could be able to enhance poly(I:C) signaling in breast cancer cells by boosting type I IFN signaling.
Our findings also show that the activation of caspases and induction of TRAIL expression by RA/poly(I:C) require the engagement of TLR3, as depletion of TLR3 abrogates caspase-8 and caspase-3 activation as well as TRAIL induction. TRAIL selectively induces apoptosis of transformed and virally infected cells. Several studies have suggested that TRAIL may have a role as a tumor suppressor since TRAIL induces apoptosis selectively in cancer cells, while normal cells are largely insensitive to its apoptotic activity. 44 Furthermore, TRAIL signaling pathway is critically involved in the immune surveillance against primary and metastatic tumors through natural killer cells. 45 We have previously reported that TRAIL expression is remarkably enhanced in breast cancer cells after RA treatment. 20 Our experiments are in agreement with our previous findings, and also show that RA can synergistically cooperate with poly(I:C) to induce TRAIL. Thus, in our study TRAIL has emerged as a likely candidate to mediate the apoptotic effect of RA/poly(I:C) combination in breast cancer cells. Notably, our results show that depletion of TRAIL abrogates apoptosis induced by RA/ poly(I:C), showing that TRAIL is a main player in RA/poly(I:C)-induced apoptosis. Based on our results, we propose that RA/ poly(I:C) treatment induces breast cancer cell apoptosis via TLR3-dependent mechanisms. RA/poly(I:C) stimulation leads to upregulation of IFNb in breast cancer cells, which in turn may act in an autocrine manner to induce the expression of TRAIL, which is ultimately responsible for cell death induction by RA/poly(I:C) in breast cancer cells. Additionally, as poly(I:C) exerts direct cytostatic/cytotoxic effects against a wide spectrum of tumor cells, we would expect that any poly(I:C)-responsive tumor cell line that keeps an intact RA signaling axis and retains the ability to produce and respond to type I IFNs could be able to mount a synergistic anti-tumor response to a combination of RA and poly(I:C).
Materials and Methods
Cell lines and reagents. Hs578T, H3396, T47D, ZR-75-1, and BT-474 cells were cultured in RPMI (Life Technologies, Carlsbad, CA, USA) or Dulbecco's modified media (Sigma, St Louis, MO, USA), in the case of SK-BR-3 cells, containing red phenol with 10% (v/v) fetal calf serum (Life Technologies) and 2 mM glutamine (Life Technologies). For the T47D cell line, medium was supplemented with 0.6 mg/ml insulin (Sigma). All cells were incubated under standard culture conditions (37 1C, 5% CO 2 ).
9-cis-RA (Sigma), the RAR-specific synthetic retinoid TTNPB (Sigma) and the RXR-specific rexinoid LG-100268 (Ligand Pharmaceuticals Inc., La Jolla, CA, USA) were dissolved in ethanol and used at 1 Â 10 À 6 M unless otherwise indicated. Poly(I:C), high molecular weight, from Invivogen (San Diego, CA, USA), was dissolved in water and used at a concentration of 50 mg/ml, with the exception of ZR-75-1 cells where 12.5 mg/ml were used. Poly(A:U) (Invivogen) was dissolved in water and used at 100 mg/ml. Type I IFNR-blocking mAb was purchased from PBL Interferon Source. Recombinant IFNb and CHX were obtained from Sigma.
